The OPTIMIZE trial found that adults aged 65 and older had similar rates of successful kidney transplantation when treated with a lower-dose immunosuppression regimen compared to standard dosing. The study was published in the Journal of The American Scociety of Nephrology by Sanders and colleagues.

Kidney transplantation remains the treatment of choice for end-stage renal disease, even in older adults. However, balancing immunosuppression against the risk of drug-related toxicity to prevent graft rejection remains a challenge in this population. A hypothesis has been raised that with reduced immune responsiveness accompanying aging, older recipients may benefit from lower immunosuppressive exposure. The OPTIMIZE study tested whether a regimen combining low-dose tacrolimus with everolim

See Full Page